Intuitive (ISRG) Q3 2026 earnings review
Intuitive sells more robots than ever, but US surgeries slow
Intuitive sold more surgical robots than ever before, but American hospitals are adding operations at the slowest rate in years. Revenue grew 22% on those system sales, and profit per share excluding one-offs rose 25%. Reported profit fell, because the robot maker booked a $450 million charge to settle an antitrust lawsuit with conduct terms it has not described.
| Revenue | $3.05B +22% from a year ago |
|---|---|
| Profit per share, excluding one-offs | $3.00 +25% from a year ago |
| US da Vinci procedure growth | 10% 16% a year ago |
| Full-year procedure outlook | Narrowed to 14–15% middle of the range unchanged at 14.5% |
⚖️ Verdict: 🔴 Bearish
The story got worse because the US slowdown deepened and nothing in the release says the delayed patients have come back. US procedure growth slipped again, to 10%, and the full-year plan now excludes the top of its old range. The good news: overhead costs grew slower than sales, and the company made its largest buyback yet.
The question now is whether the US slowdown comes from patients delaying operations or from a maturing market. If patients are delaying, US growth steadies next quarter; if the market is maturing, each new robot does less work. Fourth-quarter US procedure growth will tell.
🐂 Bull Case
Hospitals Took a Record 546 Da Vinci Systems
Intuitive earns most of its money after a robot is installed, from instruments and service, but system sales set the pace of that recurring stream. Hospitals took 546 da Vinci systems in the quarter, 28% more than a year earlier.
Systems revenue rose 30% to $769 million as a result. That line, not procedures, lifted total revenue growth to 22% from 19% last quarter.
- Da Vinci 5 systems placed: 315, up from 240 a year ago
- Systems placed under leases: 291, or 53% of the total
- Installed base: 12,094 systems, up 12%
Strong placements also carry a standing worry, because systems grew faster than the operations performed on them. By our math each installed robot handled only about 1.5% more procedures than a year ago. In the US, 143 of 335 placements replaced an existing system rather than adding one.
What to watch: fourth-quarter placements set against procedure growth. If placements keep rising near 30% while procedures grow 14%, income from usage-based leases would grow more slowly than the installed base.
Operating Costs Grew Slower Than Sales
Intuitive's operating margin, excluding one-offs, reached 41.6% of revenue, up 2.7 percentage points from a year ago. The gain came from sales and administrative costs, which fell to 17.7% of revenue from 19.0%. Those overhead costs grew 13% while revenue grew 22%.
Research spending moved the other way. It rose 28% to $321 million, half a point more of revenue than a year ago. The margin gain comes from overhead, not product work.
Gross margin needs one adjustment, because the 69.9% figure includes $28 million of refunded tariffs. Without them, by our math, gross margin was 68.9%, still above a year ago.
What to watch: fourth-quarter operating expenses, which the unchanged full-year plan requires to slow sharply. A fourth quarter inside the plan would show that this margin gain holds once research spending is funded.
Intuitive Bought Back $2.9 Billion of Stock
Intuitive repurchased 7.8 million shares for $2.94 billion in the quarter, more than in the previous three quarters combined. Buybacks had shrunk for three straight quarters, to $379 million in the second quarter, even though the board had enlarged its authorization in April.
Diluted shares fell to 351.6 million, 2.8% fewer than a year ago. That is why profit per share excluding one-offs rose 25% while net income on the same basis rose 22%. Cash and investments fell $1.83 billion in the quarter to $6.80 billion, the company said, mostly because of the buyback and factory spending.
What to watch: the size of fourth-quarter repurchases. A second quarter above $1 billion would show the robot maker has changed how it returns cash, rather than having made one large purchase.
Positives This Quarter Didn't Test
Four growth drivers from earlier quarters got no new number in the release or the data tables, so this quarter neither strengthened nor weakened them. Each needs a figure that the company usually gives on its call or in its quarterly filing.
- Surgery centres: placements to outpatient centres reached 27 last quarter; a count at or above that level would show the low-cost channel is still growing.
- Cardiac surgery: procedures grew 39% last quarter; a second growth-rate disclosure would show whether the new specialty keeps compounding.
- Japan: seven procedures gained reimbursement in June; Japanese placements above last quarter's 25 would confirm the policy change is lifting demand.
- My Intuitive+ subscriptions: a first revenue figure for the digital service would show whether it adds to recurring revenue or only to retention.
🐻 Bear Case
US Procedure Growth Slowed to 10%
Every da Vinci operation consumes instruments that Intuitive sells, so procedures drive its recurring revenue. Chief executive Dave Rosa cited 'broad-based adoption across our multi-port, single-port, and Ion platforms'. The United States, which performs 62% of da Vinci procedures, tells a narrower story.
US da Vinci procedures grew 10% from a year ago, the fifth straight slowdown. Outside the US growth held at 20%. Last quarter management attributed part of the US slowdown to patients deferring operations and said they would return.
- US procedure growth: 16%, 15%, 14%, 12%, 10% over the last five quarters
- US instrument revenue: up 18%, faster than procedures because of product mix
This matters because the full-year plan still calls for 14% to 15% procedure growth. By our math the fourth quarter needs about 14% to reach the middle, so US growth must stop slowing. The release does not say whether the deferred patients have returned.
What to watch: US procedure growth in the fourth quarter. A reading below 10% would mean the slowdown comes from something longer-lasting than delayed operations, and 2027 instrument revenue would start from a slower base.
Antitrust Settlement Costs $450 Million, Terms Unknown
Intuitive agreed in October to pay $450 million to settle the 'In re: da Vinci Surgical Robot Antitrust Litigation' class action, admitting no wrongdoing. The charge cut reported profit per share by $0.99, so reported net income fell 26%.
The money is not the main issue, because the company holds $6.8 billion in cash. The settlement also includes 'mutually agreed injunctive relief', which the release does not describe. Any change in how hospitals may reuse or service instruments would touch the line that makes up 59% of sales.
What to watch: the settlement terms in the court filing for preliminary approval. If the agreed relief loosens limits on instrument use or repair, outside refurbishers would gain ground, a threat Intuitive has not addressed by name.
Ion Procedure Growth Slowed for a Seventh Quarter
Ion is Intuitive's robotic system for lung biopsies, a much smaller business than da Vinci. The company counts on it as a second growth platform, but its growth rate keeps falling.
- Ion procedure growth: 52%, 44%, 39%, 36%, 31% over the last five quarters
- Ion revenue: $159 million, up 21%, after 39% last quarter
- Ion systems revenue: down 9%
This matters because Ion revenue was flat from the second quarter even though procedures rose 4%. Management said last quarter that US adoption had passed the halfway point, so growth now depends on each site using its system more.
What to watch: fourth-quarter Ion procedure growth. A reading that holds near 30% would show the slowdown is levelling off rather than continuing at five points a quarter.
Risks This Quarter Didn't Answer
Four standing risks got no reading in the release or the data tables. The first is the largest open item for next year, because the company had promised to put a number on it this quarter.
- Extended Use Program: longer instrument lives and lower cost per use from 2027; the promised pricing figure would show how far revenue per procedure falls.
- China: a national pricing framework for robotic surgery; the share of the installed base in provinces with price limits would show the exposure.
- Weight-loss drugs: bariatric procedures have declined for more than seven quarters; a specialty growth rate would show whether the decline has spread.
- Component and freight costs: flagged as potentially material; any gross margin commentary naming them would show whether they have started to bite.
👓 Other Themes
Tariffs Cost Less Than the Company First Thought
Intuitive's gross margin plan now assumes tariffs cost 0.9% of revenue this year, down from 1.0% in July and 1.2% in January. Most of its instruments come from Mexico and most endoscopes from Germany, so new tariffs 'could be material', the company said. The plan assumes current tariffs stay in place through December.
💲 Other KPIs
Up 22% from a year ago, the sixth straight quarter of growth near 20%. Service revenue is the fee hospitals pay to keep systems maintained, so it follows the installed base, which grew 12%, and the mix of newer da Vinci 5 systems. Operating lease revenue, the rent on leased robots, grew 23%.
Up 37% from a year ago, against revenue up 22%. Receivables are invoices hospitals have not yet paid, and by our math they now cover about 52 days of sales, up from 46. The balance has risen every quarter this year, and the release does not explain the gap with revenue.
Up 19% from a year ago and 16% since December, both slower than revenue. Inventory has grown in every quarter shown since 2024 as the robot maker adds factory capacity, but it has not outrun sales, so it adds no new pressure on cash.
🔮 Guidance
Unchanged at the middle, narrowed at both ends. The plan still has procedures growing about 14.5% this year. By our math the first nine months grew 14.7%, so the fourth quarter needs about 14% to reach the middle, close to this quarter's rate. Last year's outlook rose three times; this year's rose once, in April, and has not moved since.
Raised. The middle moved up half a point to 69.0%, the third raise this year, each of half a point: 67.5%, 68.0%, 68.5%, 69.0%. The nine-month margin stands at 69.2%, so by our math the plan has the fourth quarter below 69%. The range carries a 0.9-point tariff cost and excludes further refunds.
Unchanged. Spending grew 18% this quarter and 13.9% over nine months, so by our math the middle of the range leaves only about 7% growth for the fourth quarter. Even the top of the range allows 11%. Last year's fourth quarter carried a $70 million charitable contribution, which makes the comparison easier.
❓ Key Questions
How much will the Extended Use Program cut instrument revenue?
The company promised a pricing figure for its longer-life instruments on this quarter's call. Instruments are 59% of sales, so the per-procedure impact from 2027 is the largest unknown in next year's recurring revenue.
What does the settlement's injunctive relief require?
The $450 million payment is known; the agreed conduct terms are not. If they change limits on instrument use or repair, the economics of the instrument line shift in favour of outside refurbishers.
Have the delayed US patients started to return?
Management blamed part of the US slowdown on deferred operations and said patients would come back. US growth fell again, to 10%, so any payer or procedure data showing recovery would settle the debate.
How many systems went to surgery centres this quarter?
Outpatient centres and refurbished Xi systems are the company's route into cost-sensitive buyers. A count against last quarter's 27 would show whether that channel is still growing.
Where in China do price limits already apply?
A national pricing framework for robotic surgery is rolling out by province. The share of the China installed base in provinces with binding limits would show how much instrument pricing is at risk.